Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients

BackgroundThe incidence of irinotecan-induced diarrhea varies between 60-90%, by which the incidence of severe diarrhea is 20-40%. The objective of this phase III trial was to determine the effectiveness of the probiotic mixture containing Bifidobacterium, BB-12® and Lactobacillus rhamnosus, LGG® in...

Full description

Bibliographic Details
Main Authors: Michal Mego, Radoslav Danis, Jozef Chovanec, Silvia Jurisova, Branislav Bystricky, Stefan Porsok, Peter Konkolovsky, Vladimir Vaclav, Maria Wagnerova, Marian Streško, Bibiana Brezinova, Mária Rečková, Dagmar Sutekova, Natalia Pazderova, Mária Novisedlakova, Eva Zomborska, Sona Ciernikova, Daniela Svetlovska, Lubos Drgona
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
irinotecan
diarrhea
probiotics
colorectal cancer
beta-glucuronidase
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1168654/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1168654/full

Similar Items